Support Alert

Class 4 medicines defect information: Kyowa Kirin Bleo-Kyowa Powder for Solution for Injection 15,000 IU

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert (caution in use) for a specified batch of Bleo-Kyowa, Powder for Solution for Injection, 15,000 IU (Bleomycin sulfate). This is because in April 2017, glass particles were detected in a batch of Bleo-Medac (bleomycin sulfate) from the same manufacturer.

Further details of the affected batch and action to take are available on the MHRA website.